Press
Room
bioTheranostics Announces
Advance in Breast Cancer Clinical Management
Validation
of Proprietary Biomarkers for Prognosis of Increased Breast
Cancer Recurrence Risk
Carlsbad, CA, April 27, 2006 – bioTheranostics formerly known as Arcturus Bioscience, Inc., a leader
in molecular cancer profiling, announced today that a study,
conducted in collaboration with Mayo Clinic, demonstrated the
clinical utility of two novel genes that can identify patients
at higher risk for early breast cancer recurrence and has been
published in the April 2006 issue of Clinical Cancer Research.
Researchers at Mayo Clinic tested the
level of expression of the HOXB13 and IL17BR genes from paraffin-embedded
tumor tissue derived from postmenopausal women with early
stage, estrogen positive breast cancer who were enrolled
in a prospective tamoxifen study conducted by the North Central
Cancer Treatment Group. They demonstrated that the 2-gene
expression ratio was an independent marker of early breast
cancer relapse and overall survival in lymph node negative
breast cancer patients, but not lymph node positive tumors.
“The study with Mayo Clinic is the first
of a series of clinical studies conducted by bioTheranostics, its clinical collaborators
and independent research groups, which we expect to be published in peer reviewed
scientific journals this year,” said Antonius Schuh, Chief Executive
Officer of bioTheranostics. “We are excited about the rapidly growing
body of evidence supporting the clinical utility of HOXB13 and IL17 in the
prediction of breast cancer recurrence and are expecting our diagnostic licensing
partners to launch a testing service based on both biomarkers in 2006.”
bioTheranostics discovered both biomarkers in a collaborative study with Harvard
Medical School and Mass. General Hospital which was published in the June
2004 issue of Cancer Cell. As a result of this
study, these two biomarkers serve as the foundation of the
bioTheranostics Breast Cancer Recurrence (BCR) Technology.
Breast cancer is diagnosed in over
200,000 women each year and claims the lives of over 40,000
in the United States alone. More than 2/3 breast
cancers are hormone positive, and most of these are early stage (lymph
node negative).
About bioTheranostics
bioTheranostics, formerly Arcturus Bioscience, Inc., is a leader
in describing disease at the molecular level to enable molecular
medicine and the development of proprietary technologies
for diagnostic applications in oncology. These technologies
include the Molecular Cancer Identification (MCID) technology
which is based upon a set of clinically validated molecular
signatures relating to 90% of the most common cancers, and
the Breast Cancer Recurrence (BCR) Technology, which is based
upon a proprietary biomarker index for the prognosis of breast
cancer recurrence risk and metastatic potential. Commercialization
of the MCID Technology commenced with its licensing partners
Quest Diagnostics, and Laboratory Corporation of America
and Agendia BV for their Cancer of Unknown Primary (CUP)
diagnostic service. Quest Diagnostics has also licensed the
BCR Technology for the development of a diagnostic service.
bioTheranostics technologies and intellectual properties position
the Company to address the multi-billion dollar market opportunities
associated with the development and commercialization for
additional cancer diagnostics and inventions to cost-effectively
improve patient prognosis and response prediction in cancer
therapy. bioTheranostics has recently relocated its headquarters
from Mountain View, California to Carlsbad, California. Please
visit the bioTheranostics website at http://www.biotheranostics.com for
more information.
Forward Looking Statements
bioTheranostics cautions you that statements included in this
press release that are not a description of historical
facts are forward-looking statements. For example, statements
about the Company's expectations, beliefs, plans, objectives,
assumptions or future events or performance are not historical
facts and are all forward-looking statements. These forward-looking
statements are based upon bioTheranostics's current expectations.
The Company's actual results and the timing of events may
differ materially from those set forth in this release
as a result of certain risks and uncertainties, including,
without limitation: uncertainty regarding market acceptance
of the Company's technologies; rapid pace of technological
change in the identification and validation of proprietary
biomarkers for the prognosis of increased breast cancer
recurrence risk; uncertainty of product development
and the associated risks related to clinical trials; the
risk that the U.S. Food & Drug Administration will
not approve the Company’s products or technologies,
or that such approval will be delayed or require substantial
additional testing and information, which could result
in increased costs and uncertainty; the Company’s
ability to continue to conduct clinical trials; uncertainty
relating to third party reimbursement; the ability of the
Company or its commercial partners to convince health care
professionals and third party payers of the medical and
economic benefits of the Company's products and technologies;
the risk of loss of collaborative arrangements with third
parties; the difficulty in managing growth and successfully
managing resources; and other risks. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. We disclaim any
obligation to update these forward-looking statements,
whether as a result of new information, future events or
otherwise.
| TOP |
|
